Novo Nordisk Bullish as Demand For Blockbuster Drugs Soars
The Danish pharmaceutical giant raised its full-year guidance to reflect better pricing in the U.S. and as global demand for its hit weight-loss and diabetes drugs continues to outstrip supply.
The Danish pharmaceutical giant raised its full-year guidance to reflect better pricing in the U.S. and as global demand for its hit weight-loss and diabetes drugs continues to outstrip supply.
